Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. December 12, 2025 Predicting Toxicities and Survival Outcomes in De Novo Metastatic ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
At the 2025 UCSF-UCLA PSMA Conference, Vadim Koshkin discusses radioligand therapies for bladder cancer. He highlights that gallium-FAP-2286 imaging shows bladder cancer has the highest FAP uptake ...
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman discusses his team's work with Terbium-161 in the VIOLET clinical trial at Peter Mac. He explains Terbium-161 offers both beta and Auger electron ...
At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...
At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber discusses lutetium PSMA therapy beyond six standard cycles. He distinguishes between extended treatment (continuous administration) and ...
At the 2025 UCSF-UCLA PSMA Conference, Daniel Spratt presents on bone scan obsolescence in prostate cancer imaging. He demonstrates they fail to detect cancer with sufficient sensitivity compared to ...
At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...
Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a ...
Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback